Skip to main content

Orion Value Stock - Dividend - Research Selection

Orion Oyj

ISIN: FI0009014377, WKN: A0J3QM

Market price date: 26.01.2022
Market price: 35,33 EUR

Orion Oyj Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 23-09-2021
Cash flow
Net operating cash flow 299.100.000
Capital Expenditures -34.000.000
Free cash flow 265.100.000
Balance sheet
Total Equity 731.300.000
Liabilities & Shareholders equity 1.115.600.000
Income statement
Net income 219.900.000
Eps (diluted) 1,566
Diluted shares outstanding 140.463.000
Net sales/revenue

Fundamental ratios calculated on: 26-01-2022

Key figures 26-01-2022
Cash flow
P/C 16,59
P/FC 18,72
Balance sheet
Income statement
Div. Yield4,25%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization6.018.869.248,00 USD
IndicesSTOXX EUROPE 600,MSCI World Index
Raw Data SourceIFRS in Millionen EUR
Stock Split2004-09-15,2.000000/1.000000; 1999-07-28,2179.000000/1981.000000; 1997-12-09,7.000000/5.000000; 1993-11-23,25035.000000/17882.000000

Description of the company

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj is headquartered in Espoo, Finland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,